You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 829 A potent STING agonist in combination with a novel anti-PD-L1/PD-L2 antibody leads to significant tumor responses in checkpoint-refractory cancers

Alerts

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Combination Immunotherapies
829 A potent STING agonist in combination with a novel anti-PD-L1/PD-L2 antibody leads to significant tumor responses in checkpoint-refractory cancers
You need to be signed in to access email alerts. If you have an account log in with your user name and password. If you don't have an account you can just enter your email address in the email box below.
Sign In to Email Alerts with your Email Address